This Plain Language Summary of Publication article (PLSP) from Current Medical Research & Opinion presents results from a Phase 2b trial with 113 IgA nephropathy patients who received atacicept treatment. The trial included a 36-week double-blind phase (atacicept vs. placebo) followed by a 60-week open-label extension where all participants received atacicept.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy’ and was published in the Journal of the American Society of Nephrology.

Visit JASN using the link to read the original article.